Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05202860 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis

Study acronym: VAXAK
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 5 to 6v10
  2. Primary completion date changed from estimate of Jun 2024 to Jun 19, 2024
    • Study completion date: Jun 2035 to Jun 19, 2034
    v9
  3. Re-verified, no change to tracked fieldsv8
  4. Primary completion date: Oct 2023 to Jun 2024
    • Study completion date: Feb 2024 to Jun 2035
    v7
  5. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Start date changed from estimate of Apr 2022 to May 9, 2022v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  4. Start date: Feb 2022 to Apr 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A double-blind, randomized, placebo controlled intervention trial on patients with actinic keratosis.
Trial Details
NCT Number NCT05202860
Lead Sponsor Merete Haedersdal
Conditions
(from sponsor)		 Actinic Keratoses, Basal Cell Carcinoma, Squamous Cell Carcinoma
Related terms Basal Cell Carcinoma, Carcinoma, Squamous Cell, Keratosis, Actinic
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov